SGK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14811060	1.00	2/20
SCHEMBL29881923	1.00	2/20
SCHEMBL31511474	1.00	2/20
SCHEMBL14810298	0.74	2/20
SCHEMBL14811357	0.62	2/20
SCHEMBL14775032	0.61	2/20
SCHEMBL14775097	0.61	2/20
SCHEMBL14811603	0.61	2/20
SCHEMBL14777691	0.58	2/20
SCHEMBL14775282	0.57	2/20
SCHEMBL14812029	0.57	2/20
SCHEMBL14775002	0.56	2/20
SCHEMBL14812286	0.56	2/20
SCHEMBL14775072	0.54	2/20
SCHEMBL25263723	0.52	2/20
SCHEMBL14775053	0.52	2/20
SCHEMBL14775183	0.52	2/20
SCHEMBL22266441	0.51	2/20
SCHEMBL22266436	0.51	2/20
SCHEMBL25250375	0.51	2/20

Clinical trials — most relevant to SGK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Counteracting Deleterious Metabolic Glucocorticoid Effects With Metformin	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma	PHASE1/PHASE2	COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Study of CS231295 in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib	nan	COMPLETED
Rehabilitation Program in Patients With Acromegaly	nan	UNKNOWN
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Immune Interactions in Severe Asthma	nan	COMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SGK3 binder may also engage these)

Protein	Name	Similarity
Q9ERE3	—	1.000	Q9ERE3 →
Q5R7A7	—	1.000	Q5R7A7 →
Q8R4V0	—	1.000	Q8R4V0 →
Q6U1I9	—	0.997	Q6U1I9 →
Q9WVC6	—	0.994	Q9WVC6 →
Q6PFQ0	—	0.993	Q6PFQ0 →
SGK1	Serine/threonine-protein kinase Sgk1	0.991	landscape →
Q6GPN6	—	0.991	Q6GPN6 →
A8XNJ6	—	0.991	A8XNJ6 →
Q6GLY8	—	0.991	Q6GLY8 →
A8XJQ6	—	0.991	A8XJQ6 →
Q8R4U9	—	0.990	Q8R4U9 →
A7MB74	—	0.989	A7MB74 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.989	landscape →
P10665	—	0.989	P10665 →
RPS6KA2	Ribosomal protein S6 kinase alpha-2	0.988	landscape →
Q63531	—	0.988	Q63531 →
Q9XT18	—	0.988	Q9XT18 →
Q06226	—	0.988	Q06226 →
Q2PJ68	—	0.988	Q2PJ68 →
Q4R633	—	0.988	Q4R633 →
P18654	—	0.988	P18654 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	0.988	landscape →
P10666	—	0.987	P10666 →
Q7ZTW4	—	0.987	Q7ZTW4 →
Q12706	—	0.987	Q12706 →
Q7TPS0	—	0.986	Q7TPS0 →
P09215	—	0.986	P09215 →
PRKCD	Protein kinase C delta type	0.986	landscape →
Q9WUT3	—	0.986	Q9WUT3 →